Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Hippocratic AI acquired Grove AI in January 2026 after the startup spent two years building voice agents for clinical trial recruitment. Grove’s technology speaks with patients, collects screening information and helps match them with enrolling studies. The deal shows how
Bristol Myers Squibb announced on July 20, 2026, that it will expand its artificial intelligence infrastructure through a new NVIDIA DGX SuperPOD equipped with Vera Rubin NVL72 systems. BMS plans to use the infrastructure across several research areas, including oncology,